



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

113
123
3/19/03

In re application of:

Kim *et al.*

Appl. No. 09/814,179

Filed: March 22, 2001

For: **Method for Treatment of
Neurodegenerative Diseases**

Confirmation No. 8573

Art Unit: 1647

Examiner: Robert S. Landsman

Atty. Docket: 0609.4910002/JUK/T-M

RECEIVED

MAR 12 2003

Reply To Restriction Requirement

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the second Restriction Requirement dated **October 7, 2002**, requesting a re-election of one group to prosecute in the captioned application, Applicants hereby provisionally elect, with traverse, to prosecute Group I, represented by claims 1-3 in part, claim 4 and claims 7-8, in part, drawn to a method of identifying agents to treat a neurodegenerative disease by assaying for CCE in cells expressing a presenilin mutation. This election is made without prejudice to or disclaimer of the other claims or groups disclosed.

Applicants wish to point out that the pending claims 1-41 were restricted into Groups I-VII (page 2) and VII-XVI (page 3) in the Restriction Requirement. The Examiner listed "Group VII, claims 10 and 11 in part and 14," on page 2 and listed "Group VII, claims 10 in part and 16," on page 3. For sake of clarity, Applicants treat the restricted groups "I-VII and VII-XVI" as I-XVII, respectively, herein.